Broyhill Asset Management’s Charles River Laboratories CRL Stock Holding History

Broyhill Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.16M	Sell	12,518 -2,234	-15%	-$414K	2%	17
2025 Q4	$2.94M	Sell	14,752 -36	-0.2%	-$6.53K	2.59%	14
2025 Q3	$2.31M	Sell	14,788 -1,547	-9%	-$246K	2.03%	18
2025 Q2	$2.48M	Buy	16,335 +3,076	+23%	+$410K	2.25%	17
2025 Q1	$2M	Buy	13,259 +325	+3%	+$54.5K	1.62%	21
2024 Q4	$3.16M	Buy	+12,934	New	+$2.49M	2.78%	12

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Broyhill Asset Management's CRL Position: Q1 2026 in Review

Broyhill Asset Management reduced its Charles River Laboratories (CRL) stake by 15% in Q1 2026, selling an estimated $414K and leaving 12,518 shares worth $2.16M. The position accounts for 2% of the portfolio, ranked #17.

Broyhill Asset Management first reported a position in CRL in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.16M in Q4 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Broyhill Asset Management held 12,518 shares of Charles River Laboratories worth $2.16M as of Q1 2026.
Broyhill Asset Management sold 2,234 Charles River Laboratories shares in Q1 2026, an estimated $414K.
Charles River Laboratories made up 2% of Broyhill Asset Management's portfolio in Q1 2026, its #17 holding.
Broyhill Asset Management first reported a position in Charles River Laboratories in Q4 2024 and has held it in 6 quarters since.
Broyhill Asset Management's Charles River Laboratories position peaked at $3.16M in Q4 2024.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Broyhill Asset Management's 13F filing for Q1 2026, filed 6 May 2026.